Related Experiment Videos
Phase II study of lonidamine in patients with metastatic breast cancer. An Eastern Cooperative Oncology Group study
H I Robins1, D S Neuberg, A B Benson
1University of Wisconsin Clinical Cancer Center, Madison 53792.
Investigational New Drugs
|November 1, 1990
Abstract:
The Eastern Cooperative Oncology Group conducted a phase II study of lonidamine in patients with metastatic breast cancer. The drug was given orally to a maximum daily dose of 340 mg/m2. Forty-two patients were entered on study. One partial response was observed; there were no life-threatening toxicities. The results of this study are compared to two similar phase II trials.